Please use this identifier to cite or link to this item:
Title: Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy.
Austin Authors: Chao, Michael ;Ho, Huong;Chan, Yee ;Tan, Alwin;Pham, Trung;Bolton, Damien M ;Troy, Andrew J ;Temelcos, Catherine;Sengupta, Shomik ;McMillan, Kevin;Cham, Chee Wee;Liu, Madalena;Ding, Wei;Subramanian, Brindha;Wasiak, Jason;Lim Joon, Daryl ;Spencer, Sandra;Lawrentschuk, Nathan
Affiliation: Genesis Cancer Care Victoria, Ringwood East, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
Melbourne University; Eastern Health Clinical School, Monash University, Clayton, Victoria, Australia
St Vincent's Hospital, Fitzroy, Victoria, Australia
The Valley Private Hospital, Mulgrave, Victoria, Australia
Ringwood Private Hospital, Ringwood East, Victoria, Australia
The Bays Hospital, Mornington, Victoria, Australia
University of Melbourne, Melbourne, Victoria, Australia
Issue Date: Sep-2018 2018-03-09
Publication information: BJU International 2018; 122(3): 427-433
Abstract: To report on the dosimetric benefits and late toxicity outcomes after injection of hydrogel spacer (HS) between the prostate and rectum for patients treated with prostate radiotherapy (RT). In all, 76 patients with a clinical stage of T1-T3a prostate cancer underwent general anaesthesia for fiducial marker insertion plus injection of the HS into the perirectal space before intensity-modulated RT (IMRT) or volumetric-modulated arc RT (VMAT). HS safety, dosimetric benefits, and the immediate- to long-term effects of gastrointestinal (GI) toxicity were assessed. There were no postoperative complications reported. The mean (range) prostate size was 66.0 (25.0-187.0) mm. Rectal dose volume parameters were observed and the volume of rectum receiving 70 Gy (rV70 ), 75 Gy (rV75 ) and 78 Gy (rV78 ) was 7.8%, 3.6% and 0.4%, respectively. In all, 21% of patients (16/76) developed acute Grade 1 GI toxicities, but all were resolved completely by 3 months after treatment; whilst, 3% of patients (2/76) developed late Grade 1 GI toxicities. No patients had acute or late Grade ≥2 GI toxicities. Injection of HS resulted in a reduction of irradiated rectal dose volumes along with minimal GI toxicities, irrespective of prostate size.
DOI: 10.1111/bju.14192
ORCID: 0000-0002-8212-4220
PubMed URL: 29520983
Type: Journal Article
Subjects: #PCSM
hydrogel spacer
intensity-modulated RT
volumetric-modulated arc RT
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 9, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.